Patent: 10,722,468
✉ Email this page to a colleague
Summary for Patent: 10,722,468
Title: | Compositions for stabilizing and delivering proteins |
Abstract: | Compositions for stabilizing and delivering proteins and/or other bioactive agents are disclosed. The bioactive agents are embedded or encapsulated in a crystalline matrix. Typically the bioactive agents are in the form of micro- or nanoparticles. The crystalline matrix confers enhanced stability to the agents embedded therein relative to other microparticulate or nanoparticulate bioactive agents. The carriers are especially useful for stabilizing bioactive macromolecules, such as proteins. |
Inventor(s): | Mathiowitz; Edith (Brookline, MA), Furtado; Stacia (Pawcatuck, CT), Egilmez; Nejat (Louisville, KY), Conway; Thomas (Hamburg, NY) |
Assignee: | BROWN UNIVERSITY (Providence, RI) THERAPYX, INC. (Buffalo, NY) |
Application Number: | 15/503,891 |
Patent Claims: | see list of patent claims |
Details for Patent 10,722,468
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Janssen Biotech, Inc. | REMICADE | infliximab | For Injection | 103772 | 08/24/1998 | ⤷ Try a Trial | 2034-08-14 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 12/31/2002 | ⤷ Try a Trial | 2034-08-14 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 02/21/2008 | ⤷ Try a Trial | 2034-08-14 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 04/24/2013 | ⤷ Try a Trial | 2034-08-14 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 09/23/2014 | ⤷ Try a Trial | 2034-08-14 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 11/23/2015 | ⤷ Try a Trial | 2034-08-14 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |